Zyprexa demonstrates superior long-term efficacy in treating schizophrenia, new data show.

06 мая, 2003
In a head-to-head study comparing two atypical antipsychotic treatments for schizophrenia, Zyprexa was shown to have greater efficacy than Geodon . The results of the 28-week, double-blind, flexible-dose study were presented this week at a major international psychiatric congress. Chemical Business NewsBase - Press Release via NewsEdge Corporation : In a head-to-head study comparing two atypical antipsychotic treatments for schizophrenia, Zyprexa (olanzapine, Lilly) was shown to have greater efficacy than Geodon (ziprasidone, Pfizer). The results of the 28-week, double-blind, flexible-dose study were presented this week at a major international psychiatric congress.. Long-term treatment with Zyprexa resulted in significantly better improvement in treating positive symptoms (delusions and hallucinations), as well as negative symptoms (diminished emotion, lack of interest and depressive signs), on all efficacy measures. Also, significantly more Zyprexa patients responded positively to treatment (58.6% versus 42.5%). A significantly greater proportion of Geodon patients also required a dose reduction because of side-effects. Publication: Chemical Business NewsBase - Press Release Distributed by Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
Разделы
Новости